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InTRoduCTIon
The prevalence of depression in Parkinson's disease (PD) is estimated to be 45% (3) and major depression 17% (18). In The Study of Antidepressants in Parkinson's Disease among PD patients with the optimal antiparkinsonian treatment remission criteria were met in 44-37% and there was a ≥50% response in 68-53% of patients (19) . Depressive symptoms may worsen in OFF medication state and optimal control of motor fluctuations is associated with mood elevating effect (17) . Therefore, deep brain stimulation (DBS), which is a standard neurosurgical approach for PD, is not only of high therapeutic value in the treatment of cardinal motor signs in PD but also ameliorates depressive symptoms and quality of life (QoL). The direct antidepressive mechanism is probably associated with the impact of DBS on the medial forebrain bundle and the stimulation of the limbic system, and indirectly resulting from the improvement of motor functions (12) .
There are only a few studies in the literature relating to the assessment of QoL and depressive symptoms in PD in longterm follow-up after STN DBS. Based on some of these results, an assumption on the correlated between the improvement in motor symptoms and QoL could be found. Therefore, the authors of this study have proposed the evaluation of the QoL and depressive symptoms according to the degree of improvement in motor symptoms after the stimulation. The study was designed to compare whether there are any differences in QoL between groups with different motor response after DBS. Additionally, a special consideration was given to investigate the relationship between QoL, depressive symptoms and motor signs.
MATeRIAl and MeThodS
74 patients (38 men and 36 women) were treated with bilateral subthalamic (STN) DBS for PD between 2008-2010. The average age at surgery was 55.6 ± 7 years and the duration of the disease 12.3 years± 3.8. All participants were qualified for the subthalamic deep brain stimulation according to the CAPSIT-PD criteria (5) . Preoperatively, all patients were evaluated with Unified Parkinson's Disease Rating Scale part III (UPDRS-III), in ON=26.9±11 and OFF= 51.3 ± 14. The mean levodopa daily dose (LDD) was 1195.3 ± 392 mg and mean improvement after pharmacological treatment before the operation, calculated as (OFF-ON/OFF) was 48%. 39 of 74 (52.7%) patients were on antidepressant drugs preoperatively: tetracyclic antidepressants (TCAs) (n=8), selective serotonin reuptake inhibitors (SSRIs) (n=20), serotonin-norepinephrine reuptake inhibitors (SNRIs) (n=4), noradrenergic and specific serotonergic antidepressant (NaSSA) (n=7). 42/74 were taking dopamine agonists together with L-Dopa -pramipexole (n=18); ropinirole (n=16) and amantadine (n=8).
Details of the procedure were described previously (14) . The stimulation was initiated after 4 weeks. The quality of life was evaluated with the 39-item Parkinson's disease questionnaire (PDQ-39) and depressive symptoms with Beck's depression inventory (BDI). All the assessments were taken at baseline with no stimulation and at 6, 12 and 24-month follow-up with active DBS, additionally results were reviewed with respect to gender. The improvement from baseline in UPDRS-III with active stimulation was stratified into three groups: I) less than 30%; II) 30-60% and III) more than 60% in OFF medication state. The improvement level after initiation of the stimulation in PDQ-39 and BDI was compared with respect to stratified groups.
All data are reported as means ± standard deviation. Means were compared using ANOVA for repeated measurements and followed by post-hoc testing with a Scheffe test for multiple comparisons. A value of P ≤ 0.05 was considered statistically significant. All the statistical analysis and diagrams were created using Statistica 9 (StatSoft) software.
ReSulTS
Demographic data for the 74 patients are presented in Table I . Completed PDQ-39 and BDI data were available from both pre-and post-operative time periods in all individuals. Mean baseline scores in PDQ-39 and BDI were 64.95 ± 30.09 and 14.85 ± 10.9 respectively. At subsequent follow-up visits scheduled for 6, 12 and 24 postprocedural months with active DBS, results declined in both scales. Scores in PDQ-39 significantly decreased at 6-month follow-up to 37.32 ± 16.53 (difference from baseline 27.62; 43.3%; p<0.001), then the results had a slight upward trend to 39.5 ± 17.54 and 43.15 ± 20.54 at 12 th and 24 th postoperative month (Table II) . The deterioration in the quality of life between 6-and 24-month was statistically significant (15.6%; p=0.037). Improvement in BDI reached 25.3% (p<0.001) at 6-month follow-up, the scores remained stable at further control visits. 
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There was a notable change in motor outcomes of 55.5% (28.5; p<0 .005) at 6 month, but between 12 and 24 months scores in UPDRS-III significantly increased (19.6%) (Figure 1 ). When all participants were stratified into 3 groups according to the improvement in OFF medication UPDRS mean scores at baseline in PDQ-39 were as follows, group I 67.4 ± 29.7; group II 64.8 ± 32.0; Group III 53.4±22.0 and in BDI, I 17.4±10.5; II 14.0±9.7; III 15.1±12.0 (Table III) . The differences at baseline were significant only between group I and II compared with group III in PDQ-39 but not between any results in BDI. All the scores decreased significantly with active stimulation at 6-month follow-up and mean change in the relevant groups was: PDQ-39, group I-42.7%, 28.79 pts; II-40.7%, 26.43 pts; III-51.6%, 27.57 pts ( Figure 2) ; BDI group I -23%, 4.0 pts; II-28.1%, 3.94 pts; II-23.3 %, 3.53 pts (Figure 3) .
At further follow up (12 and 24 months) scores in PDQ-39 had an upward trend and between 6 and 24 months changed by 24.1% in group I, 38.7% III and 4.5% II. The results in BDI were almost unaffected with time. There were no statistical discrepancies between genders at any follow-up scores in both scales. However, there has been a trend of slightly higher BDI results in females (Table IV) .
dISCuSSIon
Complex symptomatology of Parkinson's diseases, including motor and non-motor features, has a significantly negative impact on patients' quality of life (9) . Studies show motor signs and depression as the strongest predictors of QoL in PD (26) Our results showed marked primary improvement in all scales, BDI, UPDRS-III and PDQ-39 after STN DBS. However, at further observations only the assessment of depressive symptoms remained at the same level, and QoL and motor symptoms worsened. Thus one can assume that the change in QoL is mostly correlated with the severity of motor signs, but certainly equally dependent on non-motor factors, which have not been tested in this study. Another major finding of this study is the most significant improvement in quality of life among patients with the best reduction of motor symptoms after DBS (more than 60% in UPDRS-III).
This study has several limitations. First, the use of self-report questionnaires of depression (BDI) and quality of life (PDQ-39), although practical, does not allow to clarify the nature and severity of depression and life standards. As the term QoL includes physical, functional, social, cultural context and emotional well-being of patients, many of these variables could not be objectively evaluated with standard questionnaires including PDQ-39. Second, both the evaluators and patients were not blinded as to whether the stimulation was switched ON or OFF. Third, application of patients' diaries could allow for a more detailed, daily evaluation of parkinsonian symptoms and everyday difficulties caused by the disease.
ConCluSIonS
This study reveals the significant reduction of depressive symptoms, motor signs and improvement of the quality of life in patients with PD after DBS STN. Motor disability was proven to be a dominant predictor of QoL. At longer followup, a significant downward trend of QoL and motor outcomes was noticed, whereas depressive symptoms remained unchanged.
dISCloSuRe
The authors have no personal financial or institutional interest in any of the drugs, materials, or devices described in this article. Our results extend those of previous studies in which similar improvements in QoL have been shown, as measured using PDQ-39 after STN DBS. In two randomized trials comparing bilateral STN DBS with best medical therapy at 6-month follow-up, results correspond to an improvement of 17% and 25% in both DBS series, with almost no change in the medication groups (23, 24) . In other studies improvement of up to 68% has been reported in PDQ-39 at up to 24 months of follow up (13, 21, 11, 20) . Interestingly, an improvement in QoL in pallidal and subthalamic DBS after 2 years in a randomized trial was only moderate and reached 11.2% and 8.9% respectively (7). In the study of Lyons at al. improvement degree in PDQ-39 changed from 32.2% to 20.6% between year one and two of follow-up. Weaver et al. reported results of DBS for two targets GPi and STN in 36-month follow up.
The improvement in PDQ-39 was similar for both targets at 6 months (25%-GPi and 27%-STN) but diminished over time to 8% in both groups (25) .
These findings are consistent with the observation from this study (13) . They also found significant positive correlations between motor outcomes and QoL with the strongest predictor of bradykinesia. Rigidity was not correlated with any aspect of QoL. According to Daniels at al. cumulative daily off time is the strongest predictor for improvement in QoL after DBS (5). Based on the results from large series of patients, the improvement in BDI may vary between 15.8-32.6%, demonstrating only moderate impact of neuromodulation on depression (25,2). A positive correlation was found between QoL and the improvement in depression but not in motor results (22) . The emotional status of PD patients might be changed after STN DBS. Anxiety tends to improve significantly at the initial period of stimulation but after 3 months may get worse, correlating with the increase of voltage and pulse-width of the stimulation (4). An interesting finding is the occurrence of impulse control disorders and dopamine
